Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
Myriad Genetics reported third-quarter 2026 revenue of $202.7 million, down 1% year over year, and raised the midpoint of its full-year revenue guidance. Cancer Care Continuum and Mental Health revenue was $163.4 million, up 1%, while Prenatal Health revenue was $39.3 million, down 12%. Gross margin was 67.9%, down 200 basis points; net loss was $43.9 million versus $27.4 million a year earlier, and cash flow used in operations was $6.5 million.
On October 19, 2026, Myriad Genetics entered a definitive agreement to sell its Prenatal Health business to Labcorp for $210 million in cash, plus related inventory value at closing. The sale is subject to customary closing conditions, including regulatory approvals, and is expected to close by early 2027; the company expects it to be accretive to revenue growth and profitability upon closing. Full-year 2026 guidance is $780 million-$790 million in revenue, including $620 million-$630 million from Cancer Care Continuum and Mental Health and approximately $160 million from Prenatal Health, with adjusted gross margin of 66%-67%.
Myriad Genetics Inc. (MYGN) granted Chief Legal & Corp Strategy officer Jennifer Lynne Fox 39,370 time-based restricted stock units on November 1, 2026, under its 2026 Employee, Director and Consultant Equity Incentive Plan. Her reported direct position following the award was 345,334 shares of common stock.
Myriad Genetics Inc's common stock is the subject of an amended ownership report stating that BlackRock Portfolio Management LLC beneficially owned 8,219,061 shares, or 8.6%, as of September 30, 2026. The reported business units had sole voting power over 7,270,669 shares and sole dispositive power over 8,219,061 shares; shared voting and dispositive power were each zero.
The reported position reflects certain business units of BlackRock, Inc. and its subsidiaries and affiliates, excluding securities beneficially owned by other business units whose holdings are disaggregated. The report also states that various persons may receive dividends or sale proceeds, but no one person's interest exceeds 5% of Myriad's outstanding common shares.
Myriad Genetics agreed to sell and assign certain assets and liabilities of its prenatal health business to Laboratory Corporation of America (Labcorp) for $210 million in cash, plus the value of the business’s inventory at closing. The business includes Foresight Carrier Screen, Prequel Prenatal Screen, FirstGene 4-in-1 Prenatal Screen and SneakPeek Early Gender Test.
Closing is subject to regulatory clearances and customary conditions, and the transaction is expected to close by early 2027. Either party may terminate if it has not closed by February 19, 2027; that date automatically extends to October 19, 2027 if regulatory clearance conditions remain unmet while all other conditions are satisfied or validly waived. Under certain circumstances, Labcorp may be required to pay Myriad a $10.5 million termination fee if failure to obtain certain regulatory clearances results in termination.
Myriad expects the transaction to be accretive to revenue growth and profitability and to strengthen its balance sheet. Labcorp expects approximately $160 million in year-one revenue, slightly accretive adjusted earnings in year one, and average diagnostics segment margins by the end of year two once fully integrated.
Myriad Genetics (MYGN) entered a separation agreement with former Chief Commercial Officer Brian Donnelly on October 6, 2026. The agreement becomes effective October 14, 2026, provided he does not revoke it before then. Donnelly’s employment ended on September 21, 2026, after his departure from the Chief Commercial Officer position effective September 16, 2026.
Under the agreement, Donnelly will receive a $1,322,294 lump-sum severance payment, among other consideration, in exchange for complying with restrictive covenants and releasing claims against the company. Certain time-based equity awards scheduled to vest within two years after the separation date will be accelerated, with annual installments deemed to vest monthly over that period. Performance-based awards remain outstanding and may vest to the extent earned if their conditions are satisfied within two years after the separation date.
MYRIAD GENETICS INC (MYGN) reported that its Chief Financial Officer, Benjamin Richard Wheeler, had 2,555 shares of common stock withheld on September 21, 2026 to satisfy tax withholding obligations linked to vesting restricted stock units. The shares were valued at $4.01 per share for this purpose. After this withholding, Wheeler directly holds 287,193 shares of MYGN common stock. No Rule 10b5-1 trading plan is reported for this transaction.
MYRIAD GENETICS INC (MYGN) disclosed an "Exit" Form 4 for Brian J. Donnelly, who, effective September 16, 2026, no longer serves as Chief Commercial Officer and is therefore no longer subject to Section 16 reporting. The filing reports Donnelly’s continuing direct holdings of common stock and performance-based restricted stock units, but no new transactions or trades. No Rule 10b5-1 plan is reported.
MYRIAD GENETICS INC (symbol: MYGN) is the issuer of record for a Form 4 filing submitted to the SEC. Sikri Vishal reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC (MYGN) reported that EVP, Commercial Vishal Sikri received a grant of 257,731 time-based restricted stock units of common stock on September 16, 2026. The award was made under the company’s 2026 Equity Incentive Plan and vests in three equal annual installments.
Each restricted stock unit represents a contingent right to receive one share of common stock. Following this grant, Sikri holds 351,224 shares of MYGN common stock directly. No Rule 10b5-1 trading plan is reported for this award.
MYRIAD GENETICS INC (MYGN) reported an initial statement of beneficial ownership for Vishal Sikri, who serves as EVP, Commercial. The filing lists 93,493 shares of Common Stock held with direct ownership after the reported event, and does not report any concurrent purchases, sales, or derivative positions.
Myriad Genetics, Inc. (MYGN) reported leadership changes in its commercial organization and reaffirmed its previously announced 2026 financial guidance. Effective September 16, 2026, Brian Donnelly ceased serving as Chief Commercial Officer and is expected to remain as a non-executive employee through September 21, 2026 to help transition his responsibilities.
The board appointed Vishal Sikri, formerly Senior Vice President, Product, as Executive Vice President, Commercial, effective September 16, 2026. Myriad highlighted Sikri’s molecular diagnostics and oncology experience and stated that it is reaffirming its full-year 2026 financial guidance announced on July 30, 2026.